Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

221. Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain

Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain Badia X, Bueno H, Gonzalez Juanatey J R, Valentin V, Rubio M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment with clopidogrel (clop) in combination with standard therapy (STh) was compared with STh alone (with acetylsalicylic acid) in patients with non-ST-elevation acute coronary syndrome (NSTEACS). Type

NHS Economic Evaluation Database.2005

222. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria

Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (...) (CREDO) trial Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Beinart S C, Kolm P, Veledar E, Zhang Z, Mahoney E M, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub W S Record Status This is a critical abstract of an economic evaluation that meets the criteria

NHS Economic Evaluation Database.2005

223. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden Lindgren P, Stenestrand U, Malmberg K, Jonsson B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined percutaneous coronary intervention (PCI) with clopidogrel plus aspirin versus aspirin alone in patients with unstable coronary artery disease (CAD). Type of intervention Treatment. Economic study type Cost-effectiveness

NHS Economic Evaluation Database.2005

224. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone Schleinitz M D, Heidenreich P A Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A combination antiplatelet therapy for the prevention of subsequent coronary events in patients with acute coronary syndrome (ACS) was examined. The combination therapy comprised clopidogrel

NHS Economic Evaluation Database.2005

225. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation

Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation Weintraub W S, Mahoney E M, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, Yusuf (...) S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of clopidogrel given for up to one year in patients with acute coronary syndromes (ACS), but without ST-segment elevation. The regimen examined was a loading dose of 300

NHS Economic Evaluation Database.2005

226. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK

Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK Karnon J, Brennan A, Pandor A, Fowkes G, Lee A, Gray D, Coshall C, Nicholls C, Akehurst R Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated treatment with clopidogrel (75 mg/day) for 2 years, followed by acetylsalicylic acid (aspirin; ASA 325 mg/day) for the remaining lifetime of the patient. This intervention was compared

NHS Economic Evaluation Database.2005

227. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events

Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation National Institute for Clinical Excellence. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. London: National Institute for Clinical Excellence (NICE) 2005: 34 Authors' objectives To provide guidance on the use of clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. Authors' conclusions This guidance applies to people who have had an occlusive vascular event, or who have symptomatic peripheral arterial

Health Technology Assessment (HTA) Database.2005

228. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. 15659723 2005 01 20 2005 01 27 2014 11 20 1533-4406 352 3 2005 Jan 20 The New England journal of medicine N. Engl. J. Med. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. 238-44 Concurrent therapy with a proton-pump inhibitor is a standard treatment for patients receiving aspirin who are at risk for ulcer. Current U.S. guidelines also recommend clopidrogel for patients who have (...) major gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin plus esomeprazole for the prevention of recurrent bleeding from ulcers in high-risk patients. We studied patients who took aspirin to prevent vascular diseases and who presented with ulcer bleeding. After the ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either 75 mg of clopidogrel daily plus esomeprazole placebo twice daily or 80 mg of aspirin daily plus 20 mg

NEJM2005

229. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. 16143698 2005 09 14 2005 09 15 2016 10 17 1538-3598 294 10 2005 Sep 14 JAMA JAMA Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. 1224-32 The benefit of clopidogrel pretreatment before (...) percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted. To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events. The PCI-Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study was a prospectively planned analysis of the 1863 patients undergoing PCI after mandated

JAMA2005

230. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. 15758000 2005 03 24 2005 03 31 2014 11 20 1533-4406 352 12 2005 Mar 24 The New England journal of medicine N. Engl. J. Med. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. 1179-89 A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate (...) reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and death. We enrolled 3491 patients, 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo. Patients received a fibrinolytic agent, aspirin, and when appropriate, heparin (dispensed according to body weight) and were scheduled

NEJM2005

231. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. 16271642 2005 11 07 2005 12 01 2015 06 16 1474-547X 366 9497 2005 Nov 05 Lancet (London, England) Lancet Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. 1607-21 Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high (...) . The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear. 45,852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 mg daily. 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to continue until

Lancet2005

232. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

NIHR HTA programme2004

233. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page

NIHR HTA programme2004

234. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. 15276392 2004 07 27 2004 08 19 2015 06 16 1474-547X 364 9431 2004 Jul 24-30 Lancet (London, England) Lancet Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled (...) trial. 331-7 Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo

Lancet2004

235. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) coronary syndromes: a systematic review and economic evaluation Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R CRD summary This review found that clopidogrel in combination with standard therapy was significantly more effective than aspirin alone for the treatment of acute coronary syndromes. Overall, this was a well-conducted review and the authors' conclusions are supported by the evidence presented. Authors' objectives To review the clinical

DARE.2004

236. Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose: evidence from a meta-analysis

Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose: evidence from a meta-analysis Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose: evidence from a meta-analysis Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose: evidence from a meta-analysis Biondi-Zoccai G G, Agostoni P, Testa L, Abbate A, Parisi Q, Burzotta F, Trani C, Mongiardo R (...) , Vassanelli C, Biasucci L M CRD summary This review compared clopidogrel with ticlopidine, in addition to aspirin, for the prevention of complications in patients undergoing implantation of coronary stent devices. The results indicated that clopidogrel with a loading regimen was as good as or better than ticlopidine, whereas without a loading regimen it was worse. However, with only five studies included in the review, these findings may not be definitive. Authors' objectives To compare the efficacy

DARE.2004

237. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome

Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute (...) for Clinical Excellence. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 80. 2004 Authors' objectives To provide guidance on the use of clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome. Authors' conclusions 1.1 Clopidogrel, in combination with low-dose aspirin, is recommended for use in the management of non-ST-segment-elevation acute coronary syndrome

Health Technology Assessment (HTA) Database.2004

238. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (...) in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified

Health Technology Assessment (HTA) Database.2004

239. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two alternative antiplatelet therapies, aspirin (325 mg orally per day) and clopidogrel (75 mg orally per day), were examined. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients with peripheral arterial disease, a non

NHS Economic Evaluation Database.2004

240. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute (...) the use of 12-month clopidogrel in combination with aspirin for the prevention of morbidity and mortality associated with non-ST-segment elevation acute coronary syndrome (ACS). The combined therapy was compared with standard therapy including aspirin. Three alternative strategies (representing treatment with clopidogrel over a 1-, 3- or 6-month duration) were also considered. Type of intervention Secondary prevention. Economic study type Cost-utility analysis Study population The study population

NHS Economic Evaluation Database.2004